口腔颌面-头颈部恶性肿瘤的同步放化疗

doi:10.3969/j.issn.1005-4979.2013.06.001

摘要/Abstract

摘要： 局部晚期、切缘阳性和颈部淋巴结包膜外侵犯，是影响口腔颌面?鄄头颈肿瘤预后的重要因素。近年来前瞻性临床研究显示，同步放化疗能改善部分患者的疗效，即适合化疗的、具有上述一或二项危险因素的患者。研究提示淋巴结包膜外侵犯是术后同步放化疗的绝对适应证。本文在同步放化疗协同提高疗效理论依据的基础上，对同步放化疗药物的选择、使用方法、与放疗联合应用的次序、治疗毒性和注意事项进行了全面阐述，以进一步推动口腔颌面?鄄头颈肿瘤同步放化疗的临床实践。

关键词: 口腔颌面-头颈部； , 恶性肿瘤； , 同步放化疗； , 研究进展

Abstract: Patients suffered with oral and maxillofacial-head and neck carcinoma in locally advanced stage, microscopically involved resection margins and extracapsular spread (ECS) of tumor from neck nodes are the most significant prognostic factors for poor outcomes. Recent prospective randomized trials have shown concurrent chemoradiotherapy improves outcome in patients with one or both of those risk factors which are medically fit to receive chemotherapy. ECS appears to be an absolute indication for postoperative concurrent chemoradiotherapy. In accordance with theoretical basis of concurrent chemoradiotherapy improving patients' outcomes, the present article suggests the choice of chemotherapy drugs, dosage, combined order with radiation and toxicity, which may further promote the clinical practice of concurrent chemoradiotherapy for oral and maxillofacial-head and neck carcinoma patients.

Key words: oral and maxillofacial-head and neck carcinoma, concurrent chemoradiotherapy, development

中图分类号:

R783.81

王中和. 口腔颌面-头颈部恶性肿瘤的同步放化疗[J]. 《口腔颌面外科杂志》, 2013, 23(6): 403-408.

WANG Zhong-he. Concurrent Chemoradiotherapy of Oral and Maxillofacial-Head and Neck Carcinoma[J]. 《Journal of Oral and Maxillofacial Surgery》, 2013, 23(6): 403-408.

https://journal06.magtech.org.cn/Jweb_joms/CN/Y2013/V23/I6/403

参考文献

[1] National Comprehensive Cancer Network.头颈部肿瘤临床实践指南（中国版，2010年第一版）[EB/OL]. [2013-06-25]. http://www.nccChina.org/nccn-guidelines-China.aspx.

[2] Blanchard P, Hill C, Guihenneuc-Jouyaux C, et al. Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer[J]. J Clin Epidemiol,2011,64(9):985-992.

[3] Jeremic B,Shibamoto Y, Stanisavljevic B, et al. Radiationtherapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial[J].Radiother Oncol, 1997,43(1):29-37.

[4] Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase Ⅲ comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer[J]. J Clin Oncol 2003,21(1):92-98.

[5] Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2004 ,350(19):1937-1944.

[6] Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer[J]. N Engl J Med, 2004, 350(19):1945-1952.

[7] Rewari AN, Haffty BG, Wilson LD, et al. Postoperative concurrent chemoradiotherapy with mitomycin in advanced squamous cell carcinoma of the head and neck: results from three prospective randomized trials[J]. Cancer J, 2006, 12(2):123-129.

[8] Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) [J]. Head Neck, 2005, 27(10):843-850.

[9] Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/ intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck[J]. Int J Radiat Oncol Biol Phys,2012, 84(5) :1198-1205.

[10] Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma[J]. J Natl Cancer Inst, 1999, 91(24):2081-2086.

[11] Argiris A, Karamouzis MV, Johnson JT, et al. Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer[J]. Laryngoscope. 2008, 118（3）: 444-449.

[12] Zakotnik B, Smid L, Budihna M, et al. Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report[J]. Int J Radiat Oncol Biol Phys, 1998, 41（5）:1121-1127.

[13] Browman GP, Hodson DI, Mackenzie RJ, et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis[J]. Head Neck, 2001, 23(7):579-589.

[14] Fortin A, Caouette R, Wang CS, et al. A comparison of treatment outcomes by radiochemotherapy and postoperative radiotherapy in locally advanced squamous cell carcinomas of head and neck[J]. Am J Clin Oncol, 2008, 31（4）:379-383.

[15] Watkins JM, Zauls AJ, Wahlquist AH, et al. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer[J]. Laryngoscope, 2010, 120(2):236-242.

[16] Fesneau M, Pointreau Y, Chapet S, et al. Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study[J]. Int J Radiat Oncol Biol Phys, 2010, 76(1):154-163.

[17] Lee YJ, Lee CG, Cho BC, et al. Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer[J]. Head Neck, 2010, 32(2):235-243.

[18] Taylor SG 4th, Murthy AK, Griem KL, et al. Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results[J]. Head Neck,1997, 19(8) :684-691.

[19] Katori H, Tsukuda M, Taguchi T. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck[J]. Cancer Chemother Pharmacol, 2007, 59(6):789-794.

[20] Chougule PB, Akhtar MS, Rathore R, et al. Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53) [J]. Head Neck, 2008,30(3):289-296.

[21] Lee KC, Lee SH, Lee Y, et al. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 71(1):187-191.

[22] Choe KS, Salama JK, Stenson KM, et al. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer[J]. Radiother Oncol, 2010, 97(2):318-321.

选择文件类型/文献管理软件名称

选择包含的内容